Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Salmonella enterica serovar typhi ZH9

A formulation containing a live-attenuated strain of the bacterium Salmonella typhi, with potential immunomodulating and antineoplastic activities. Upon administration of Salmonella enterica serovar Typhi ZH9, the Salmonella in ZH9 may cause a Salmonella-induced systemic reprogramming of myeloid cells within the tumor microenvironment (TME). This enhances the recruitment of innate and adaptive immune cells, including the upregulation of co-stimulatory and major histocompatibility (MHC) molecules on dendritic cells (DCs), natural killer (NK) cells, CD4+ and CD8+ T cells, monocytes, and macrophages. This may alleviate immune suppression, restore immune fitness and tissue immunosurveillance and re-activate an anti-tumor immune response.
Code name:M01ZH 09
M01ZH-09
M01ZH09
ZH 9
ZH-9
ZH9
Search NCI's Drug Dictionary